Related Experiment Video

Updated: Aug 20, 2026

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain
05:17

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain

Published on: May 26, 2023

Effect of chronic antidepressant treatment on beta-receptor coupled signal transduction cascade. Which effect matters

G Holoubek1, M Nöldner, K Treiber

  • 1Department of Pharmacology, Biocenter, University of Frankfurt, 60439 Frankfurt, Germany.

Pharmacopsychiatry
|November 17, 2004
PubMed
Abstract

Insights

Chronic antidepressant treatment effects on beta-receptor signaling vary. While some drugs down-regulate beta-receptors, changes in CREB and BDNF protein levels are inconsistent, making a single common target difficult to identify.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Chronic antidepressant drug administration can lead to beta-receptor down-regulation.
  • The cyclic AMP (cAMP) pathway and transcription factors like CREB are involved in antidepressant drug signaling.
  • Previous studies show inconsistent alterations in CREB and BDNF levels following antidepressant treatment.

Purpose of the Study:

  • To investigate the effects of chronic treatment with reboxetine, citalopram, and imipramine on the beta-receptor signal transduction cascade.
  • To assess potential antidepressant effects using the forced swimming test.

Main Methods:

  • Animals received chronic treatment with reboxetine, citalopram, or imipramine for 9 or 19 days.
  • Beta-receptor density, CREB protein, and BDNF protein levels were measured.
  • The forced swimming test was used to evaluate antidepressant activity.

Main Results:

  • Reboxetine and imipramine down-regulated beta-receptor density, but citalopram did not.
  • CREB protein levels showed minor increases after 9 days and were unchanged or reduced after 19 days.
  • BDNF protein levels were slightly elevated only after 9 days of treatment; citalopram exhibited the most activity.

Conclusions:

  • The study highlights divergent effects of different antidepressant drugs on the beta-receptor signaling pathway.
  • It is challenging to pinpoint a single, common molecular target within this cascade for all tested antidepressants.
  • Findings suggest complexity in the downstream signaling of antidepressant action.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

The Forced Swim Test as a Model of Depressive-like Behavior05:42

The Forced Swim Test as a Model of Depressive-like Behavior

Published on: March 2, 2015

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...